521074-29-3

Upstream product

• 195992-04-2 methyl 2-ethenyl-3-nitrobenzoate 
• 22621-41-6 2-hydroxy-3-nitro-benzoic acid methyl ester 
• 521074-27-1 3-nitro-2-vinylbenzoic acid 
• 521074-26-0 methyl 3-nitro-2-{[(trifluoromethyl)sulfonyl]oxy}benzoate 
• 1361537-90-7 tert-butyl 3-nitro-2-vinylphenylcarbamate 

Downstream Products

• 521074-32-8 4-bromo-N-[8-ethyl-3-(hydroxymethyl)-7-quinolinyl]benzamide 
• 521074-33-9 4-bromo-N-[3-(chloromethyl)-8-ethyl-7-quinolinyl]benzamide hydrochloride 
• 521071-30-7 N-[8-ethyl-3-(1-pyrrolidinylmethyl)-7-quinolinyl]-4'-fluoro-[1,1'-biphenyl]-4-carboxamide 
• 521074-31-7 N-(3-amino-2-ethylphenyl)-4-bromobenzamide 

Relevant academic research and scientific papers

Melanin-concentrating hormone receptor 1 antagonists. Synthesis and structure-activity relationships of novel 3-(aminomethyl)quinolines

It was found that 3-(aminomethyl)quinoline derivatives showed high binding affinities for melanin-concentrating hormone receptor 1 (MCHR1) with reduced affinity for serotonin receptor 2c (5-HT2c) when the dihydronaphthalene nucleus of compound 1 (human MCHR1, IC50 = 1.9 nM; human 5-HT2c receptor, IC50 = 0.53 nM) was replaced by other bicyclic core scaffolds. Among the synthesized compounds, 8-methylquinoline derivative 5v especially showed high binding affinity (IC50 = 0.54 nM), potent in vitro antagonistic activity (IC50 = 2.8 nM) for MCHR1, and negligible affinity for 5-HT2c receptor (IC50 > 1000 nM). Oral administration of 5v significantly and dose-dependently suppressed nocturnal food intake in diet-induced obese rats and did not affect food intake in MCHR1-deficient mice. These results and rat pharmacokinetic study findings suggested that compound 5v is a highly potent, orally bioavailable, and centrally acting nonpeptide MCHR1 antagonist.

QUINOLINE COMPOUND

A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein Aris a cyclic group optionally having substituent(s) ;Xis a bond or a spacer having a main chain of 1 to 6 atoms;R1 and R2are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s);Yis a divalent hydrocarbon group optionally having substituent(s) (except CO);R3is a hydrogen atom or a hydrocarbon group optionally having substituent(s); andring A and ring Bmay further have substituents, and when ring B further has a substituent, the substituent may be linked to R1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.